Spero Therapeutics (SPRO) Cash & Equivalents (2016 - 2026)

Spero Therapeutics (SPRO) has 11 years of Cash & Equivalents data on file, last reported at $56.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 14.81% year-over-year to $56.1 million; the trailing twelve-month figure through Mar 2026 stood at $56.1 million (up 14.81% YoY), and the FY2025 full-year result was $40.3 million, down 23.87% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $56.1 million, up from $40.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $109.1 million in Q4 2022 and bottomed at $31.2 million in Q2 2025.
• The 5-year median for Cash & Equivalents is $63.5 million (2024), against an average of $66.0 million.
• The widest annual swing landed in 2022, when Cash & Equivalents slumped 55.3%; it then jumped 85.99% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $109.1 million in 2022, then sank by 30.04% to $76.3 million in 2023, then sank by 30.71% to $52.9 million in 2024, then fell by 23.87% to $40.3 million in 2025, then soared by 39.4% to $56.1 million in 2026.
• The last three Cash & Equivalents figures came in at $56.1 million (Q1 2026), $40.3 million (Q4 2025), and $48.6 million (Q3 2025), per Business Quant data.

Peer Comparison